Rare Blood Disorders.

Rare Blood Disorders

Some of the most serious unmet patient needs today are in the field of haematology, and we are committed to significantly improving the health and lives of people with rare blood disorders around the world through groundbreaking science.

With our acquisitions of Bioverativ and Ablynx in 2018, and our own in-house programs, we have the opportunity to apply our legacy of a patient-centred approach with our commitment to innovation and rigorous clinical research to make a meaningful difference for people affected by rare blood disorders.

Our Focus

Our Rare Blood Disorders franchise includes a haemophilia portfolio incorporating extended half life factor products, therapies for cold agglutinin disease, sickle cell disease, and beta thalassemia. We also have the potential to launch several more therapies over the next five years, providing the opportunity to bring new therapies to patients who currently have few options.